RecruitingNCT07303140

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives


Sponsor

University Hospital, Strasbourg, France

Enrollment

30 participants

Start Date

Oct 18, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.


Eligibility

Min Age: 1 MonthMax Age: 21 Years

Inclusion Criteria3

  • Minors: from birth to 17 years
  • Adults: 18 to 21 years
  • Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.

Exclusion Criteria1

  • \- Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Service de pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07303140


Related Trials